Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

743
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
743
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

775
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
775
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

476
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
476
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

793
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
793
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

809
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
809
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

342
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
342

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical indications for positron emission tomography myocardial perfusion imaging and myocardial blood flow quantification: An American Society of Nuclear Cardiology position statement.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2026
Same author

Durable remission of cardiac sarcoidosis following discontinuation of methotrexate: A prospective cohort study.

Respiratory medicine·2025
Same author

Test-retest Assessment of Biventricular Myocardial Oxidative Metabolism and Perfusion in Pulmonary Hypertension Patients Using <sup>11</sup>C-acetate PET Imaging: A Pilot Study.

Molecular imaging and biology·2025
Same author

Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.

Brain sciences·2024
Same author

Chest Pain Evaluation: Diagnostic Testing.

CJC open·2024
Same author

Atlas for reporting PET myocardial perfusion imaging and myocardial blood flow in clinical practice: an information statement from the American Society of Nuclear Cardiology.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·2023

Related Experiment Video

Updated: Apr 23, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

21.6K

Myocardial viability: it is still alive.

Siok P Lim1, Brian A Mc Ardle1, Rob S Beanlands2

  • 1Department of Medicine, National Cardiac PET Centre, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Seminars in Nuclear Medicine
|September 20, 2014
PubMed
Summary

Viability imaging helps guide revascularization decisions in heart failure patients with ischemic cardiomyopathy. Advanced imaging like PET and cardiac MRI offer higher accuracy for improved patient outcomes.

More Related Videos

Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

7.4K
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

2.9K

Related Experiment Videos

Last Updated: Apr 23, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
08:13

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

21.6K
Pre-clinical Model of Cardiac Donation after Circulatory Death
06:26

Pre-clinical Model of Cardiac Donation after Circulatory Death

Published on: August 2, 2019

7.4K
In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
05:04

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter

Published on: February 22, 2022

2.9K

Area of Science:

  • Cardiology
  • Medical Imaging

Background:

  • Heart failure is a major health issue in industrialized nations, often stemming from coronary artery disease.
  • Revascularization can improve outcomes for heart failure patients, with viability assessment aiding treatment decisions.

Purpose of the Study:

  • This review evaluates the role and modalities of viability imaging in managing ischemic cardiomyopathy.
  • It highlights the importance of imaging in complex revascularization decisions for high-risk patients.

Main Methods:

  • The review discusses Positron Emission Tomography (PET), Single-Photon Emission Computed Tomography (SPECT), cardiac Magnetic Resonance Imaging (MRI), and dobutamine echocardiography.
  • It emphasizes considering clinical factors, modality availability, and local expertise when selecting an imaging technique.

Main Results:

  • Advanced imaging techniques like PET and cardiac MRI are generally preferred due to higher accuracy.
  • Viability imaging is crucial for identifying patients who may benefit from revascularization.

Conclusions:

  • Viability imaging is valuable in managing ischemic cardiomyopathy, guiding revascularization and implantable cardioverter-defibrillator decisions.
  • Different imaging modalities should be viewed as complementary, with advanced options often providing superior results.